<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256876</url>
  </required_header>
  <id_info>
    <org_study_id>EC/2018/1267</org_study_id>
    <nct_id>NCT04256876</nct_id>
  </id_info>
  <brief_title>TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I)</brief_title>
  <acronym>TaPaS</acronym>
  <official_title>A Randomized-controlled Trial Comparing Transcutaneous Tibial Nerve Stimulation (TTNS) Versus Sham Therapy on Short Term Continence Outcomes in Children With the Idiopathic Overactive Bladder Syndrome: the TaPaS Trial Part I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part I of the TaPaS trial forms part of a twofold clinical RCT:

      Part 1) A prospective RCT comparing the efficacy of transcutaneous tibial nerve stimulation
      (TTNS) with TTNS sham therapy for children with idiopathic overactive bladder on clinical and
      patient reported outcomes (PROMS).

      Part 2) A prospective RCT comparing TTNS versus Percutaneous tibial nerve stimulation (PTNS)
      on clinical outcomes and PROMS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non invasive neuromodulation therapy for children with the overactive bladder syndrome is a
      highly under investigated topic in medical literature.

      Only 2 studies ( Patidar et al. and Boudaouid et al.) investigated the use of tibial nerve
      stimulation with adhesive electrodes.

      1) In the first trial the superiority of TTNS vs.Sham therapy for the therapeutic management
      of children with OAB naive to any pharmacological treatment will be examined.

      Clinical outcomes will be assessed by the use of daytime and nighttime bladder diaries.

      Assessment of outcomes at baseline, after 6 weeks and 12 weeks of treatment, and
      investigation of mean time to partial or complete relapse following 6 weeks observation.

      After a wash-out period of 6 weeks, patients from the part I Sham group will be able to be
      included for TaPaS part II.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized-controlled superiority trial:
TTNS(Active treatment) vs. Sham TTNS (placebo)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants are blinded for the given treatment ( Active TTNS vs. Sham TTNS) by the care provider ( Physiotherapist).
The outcomes assessor (the pediatric urologist) isn't aware of the treatment neither.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean voided volume per void</measure>
    <time_frame>12 weeks</time_frame>
    <description>Difference in mean voided volume per void in percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum voided volume (ml)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Maximal voided volume per void ( ml) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of urgency incontinence episodes / 24 h.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reduction in number of incontinence episodes per 24 hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime voiding frequency</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean voiding frequency per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction on urinary symptoms reported by parents</measure>
    <time_frame>12 weeks</time_frame>
    <description>Subjective satisfaction reported by the parents - on a 7 point likert scale- &quot;How satisfied of dissatisfied would you be if the bladder symptoms of your child would persist like this?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>At 12 weeks of treatment + at 6 weeks of observational period without treatment.</time_frame>
    <description>Time to complete or partial relapse to baseline symptoms after 12 weeks of treatment during the observational period of 6 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Overactive Bladder Syndrome</condition>
  <arm_group>
    <arm_group_label>Active TTNS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTNS sham intervention</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld.
Home therapy: Daily stimulation during 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TTNS</intervention_name>
    <description>See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.</description>
    <arm_group_label>Active TTNS</arm_group_label>
    <other_name>Transcutaneous tibial nerve stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TTNS Sham</intervention_name>
    <description>See section 'arms'</description>
    <arm_group_label>TTNS sham intervention</arm_group_label>
    <other_name>Sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children between 5 and 12 years old, clinically diagnosed with the idiopathic
             overactive bladder syndrome with urinary incontinence (daytime and/or nighttime)

          -  Untreated, except from urotherapy.

        Exclusion Criteria:

          -  Enuresis nocturna due to nocturnal polyuria

          -  Dysfunctional voiding

          -  Neurogenic bladder

          -  Psychiatric disorders, behavioural disturbances or mental disabilities

          -  Treated before with pharmacotherapy or invasive therapies for OAB

          -  Children with parents unable to record reliably micturition diaries.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Françoise Spinoit, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Ghijselings, MD</last_name>
    <phone>+3293321353</phone>
    <email>lynn.ghijselings@uzgent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Françoise Spinoit, Professor</last_name>
    <phone>+3293326495</phone>
    <email>annefrançoise.spinoit@uzgent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Gent</city>
        <state>East-Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Ghijselings, MD</last_name>
      <phone>+3293321353</phone>
      <email>lynn.ghijselings@ugent.be</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Françoise Spinoit, MD, PhD</last_name>
      <phone>+3293326495</phone>
      <email>annefrançoise.spinoit@uzgent.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Boudaoud N, Binet A, Line A, Chaouadi D, Jolly C, Fiquet CF, Ripert T, Merol ML. Management of refractory overactive bladder in children by transcutaneous posterior tibial nerve stimulation: A controlled study. J Pediatr Urol. 2015 Jun;11(3):138.e1-10. doi: 10.1016/j.jpurol.2014.09.013. Epub 2015 Mar 31.</citation>
    <PMID>25979217</PMID>
  </reference>
  <results_reference>
    <citation>Patidar N, Mittal V, Kumar M, Sureka SK, Arora S, Ansari MS. Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder: A preliminary report. J Pediatr Urol. 2015 Dec;11(6):351.e1-6. doi: 10.1016/j.jpurol.2015.04.040. Epub 2015 Jul 29.</citation>
    <PMID>26279104</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Ghent</investigator_affiliation>
    <investigator_full_name>Urologie</investigator_full_name>
    <investigator_title>Professor Dr. Anne-Françoise Spinoit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

